Sept 7 (Reuters) - Gilead Sciences Inc's , opens new tab Trodelvy extended by 3.2 months the survival of patients with advanced stages of a common type of breast cancer, according to data released ...

Gilead Sciences' Trodelvy failed to improve survival for patients with advanced bladder cancer and only modestly extended the lives of previously treated patients with late-stage lung cancer in a ...

Gilead Sciences said Monday that Trodelvy, its “smart-bomb” medicine that combines an antibody with chemotherapy, did not significantly extend the lives of patients with metastatic non-small ...

Gilead Sciences said on Monday a late-stage trial of its antibody-drug conjugate Trodelvy failed to show that it significantly improved survival for previously treated patients with advanced non ...

Gilead Sciences, Inc. (GILD) announced on Monday that its late-stage study showed a combination of its drug Trodelvy with Merck's (MRK) immuno-oncology agent Keytruda significantly improved ...

Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale. Gilead needs Arcellx more than ever.

Trodelvy’s new survival showing may come as a pleasant surprise for Gilead investors, but the debate around its competitive profile against AstraZeneca and Daiichi Sankyo’s Enhertu is far from ...

Gilead is conducting several other Trodelvy studies, including a trial of the drug as an initial treatment for triple-negative breast cancer patients who do not express PD-L1. Sponsored Bank Accounts ...

Gilead Sciences' announced topline results from the Phase 3 TROPiCS-04 study on Trodelvy for metastatic urothelial cancer. The study did not meet the primary endpoint of overall survival but ...

Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer. Sep. 05, 2024 8:00 AM ET Gilead Sciences, Inc. (GILD) ...